The goal of this clinical research study is to find the highest tolerable dose of anti-CD137 (utomilumab) that can be given in combination with CD8+T cells, IL-2 (aldesleukin), and cyclophosphamide in patients with ovarian cancer. The effect of this combination treatment will also be studied.